Form 4: Celldex Therapeutics Executive Receives Stock Options

Celldex Therapeutics reports the grant of incentive stock options to SVP of Regulatory Affairs, Margo Heath-Chiozzi.

Summary

• Margo Heath-Chiozzi, Senior Vice President of Regulatory Affairs at Celldex Therapeutics, Inc., was granted 95,000 incentive stock options.
• The options have an exercise price of $34.09 per share.
• The grant date was June 25, 2026.
• These options are part of the company's 2021 Omnibus Equity Incentive Plan.
• Vesting begins on June 25, 2027, with 25% vesting on that date, and the remaining 75% vesting quarterly over the subsequent 12 quarters.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant financial or strategic development for the company.

Positives

• Grant of stock options to a key executive, indicating potential alignment of executive interests with shareholder value.
• The stock options are part of a formal equity incentive plan designed to retain and motivate employees.

Risks

• The value of the stock options is subject to the future performance of Celldex Therapeutics' stock price.
• If the stock price does not exceed the exercise price of $34.09, the options may not be exercised profitably.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the successful vesting of the options.

Industry Context

StockSavvy.ai notes that the grant of stock options to senior executives is a common practice in the biotechnology and pharmaceutical industry, used as a tool for executive compensation and to incentivize long-term performance and alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The grant of options does not immediately impact share count but represents potential future dilution if exercised. It also signals management's commitment to the company's long-term success.
• Employees: The equity incentive plan structure may motivate other employees through similar programs.
• Management: The executive's compensation is tied to company performance through these options.

Next Steps

• The executive will be eligible to exercise vested options according to the specified schedule.
• The company will continue to operate under its 2021 Omnibus Equity Incentive Plan.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Options, Executive Compensation, Equity Incentive Plan, Regulatory Affairs, Insider Trading, SEC Filing